Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

• the present invention relates to C- or N-(imidazolylalkyl) substituted cyclic amine compounds having valuable pharmacological properties, especially central nervous system (“CNS”) activities and activity against inflammatory disease and allergic conditions.
• CNS central nervous system
• Compounds of this invention are agonists or antagonists of the histamine-H 3 receptor.
• H 3 receptor sites are known and are of current interest to those skilled in the art as a therapeutic target.
• U.S. Pat. No. 4,767,778 (Arrang et al) discloses certain imidazoles that behave as agonists of the H 3 receptors in rat brain.
• European Patent Application No. 0 420 396 A2 (Smith Kline & French Laboratories Limited) and Howson et al., ( Bioorg. & Med. Chem. Letters , (1992), Vol. 2 No. 1, pp. 77-78) describe imidazole derivatives having an amidine group as H 3 agonists. Van der Groot et al. ( Eur. J. Med. Chem . (1992) Vol. 27, pp.
• A, m, n, R 1 and R 2 are defined therein.
• the compounds are disclosed as being useful for treating various disorders, in particular such caused by allergy-induced responses.
• WO 93/12093 discloses imidazolylmethyl piperazines and diazepines as H 3 antagonists.
• U.S. patent application, Ser. No. 08/965,754, filed Nov. 7, 1997 discloses imidazolylalkyl substituted heterocyclic ring compounds as H 3 receptor antagonists.
• U.S. patent application, Ser. No. 08/966,344, filed Nov. 7, 1997 discloses phenylalkylimidazoles as H 3 receptor antagonists.
• novel compounds having agonist or antagonist activity on H 3 receptors would be a welcome contribution to the art.
• This invention provides just such a contribution by providing novel compounds having H 3 agonist or antagonist activity.
• This invention provides novel compounds with H 3 receptor agonist or antagonist activity with the inventive compound having the general formula depicted in Formula I, including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compounds:
• G is a spacer moiety selected from the group consisting of C 1 -C 7 alkyl, C 2 -C 7 alkenyl, C 2 -C 7 alkynyl, C 1 -C 7 alkyl-NHCO—, and —SO2—, with said alkyl, alkenyl or alkynyl being optionally substituted with one or more groups selected from substituted or unsubstituted alkyl, aryl, aralkyl, alkylaryl, —O—alkyl, and -CO 2 -alkyl, and wherein said substituents are selected from the group consisting of alkyl, aryl, aralkyl, and halogen; and
• T is a six-membered ring or a seven-membered ring containing two ring nitrogens and belonging to the formula a shown below, with said T ring being connected to said G moiety at either a ring carbon atom of ring T or a ring nitrogen atom of ring T:
• n 1 or 2;
• R 2 , R 3 , R 4 , R 5 , R 6 and R 7 can be the same or different with the proviso that no two of said R 3 , R 4 , R 5 and R 6 can be bound to the same carbon atom of ring T except when at least one of said R 3 , R 4 , R 5 and R 6 is H,
• R 3 , R 4 , R 5 , and R 6 can be the same or different and are independently selected from the group consisting of H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, aryl, aralkyl, alkylaryl, —C( ⁇ O)R 8 , —CO 2 R 8 , —SO 2 R 8 , S(O)R 8 , —C(O)NR 8 R 9 , —C( ⁇ NR 8 )NR 8 R 9 , —C—O—R 8 , —OC(O)R 8 , —N(R 8 ) 2 , —NR 8 R 9 , —SR 8 , —OH, —OR 8 , —CH 2 OR 8 , —CH 2 N(R 8 ) 2 , —CH 2 SR 8
• substituted in the phrase “substituted or unsubstituted” refers to appropriate substitution with suitable moieties such as, for example, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, aralkyl, alkylaryl, cycloalkyl, heterocyclic or halogen.
• This invention additionally provides methods for preparing compounds of Formula I.
• compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula I.
• This invention further provides a method of treating allergy, (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)—i.e., a method of lowering intraocular pressure, sleeping disorders (e.g., hypersomnia, somnolence, narcolepsy and sleeplessness, such as insomnia), states of hyper and hypomotility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's Disease, schizophrenia, and migraine) comprising administering an effective amount of a composition comprising a compound of Formula I to a patient in need of such treatment.
• allergy for example asthma
• inflammation for example asthma
• hypertension such as glaucoma
• raised intraocular pressure such as glaucoma
• sleeping disorders e.g., hypersomnia, somnolence, narcolepsy and sleeplessness, such as insomnia
• the invention also covers the aspect of using a compound of Formula I for the treatment of upper respiratory tract disorders.
• the invention also covers the aspect of using a compound of Formula I in combination or admixture with an Hi receptor antagonist for the treatment of upper respiratory tract disorders.
• alkyl represents a straight or branched, saturated hydrocarbon chain having from 1 to 6 carbon atoms
• cycloalkyl represents a saturated carbocyclic ring having from 3 to 6 carbon atoms
• halogen represents fluoro, chloro, bromo or iodo
• aryl represents a carbocyclic group having from 6 to 14 carbon atoms and having at least one benzenoid ring, with all available substitutable aromatic carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted with 1 to 3 R 9 groups, each independently selected from halo, alkyl, hydroxy, loweralkoxy, phenoxy, amino, loweralkylamino, diloweralkylamino, polyhaloloweralkyl, and polyhaloloweralkoxy.
• Preferred aryl groups include phenyl and substituted phenyl, 1-naphthyl, 2-naphthyl and indanyl;
• heterocyclic represents, in addition to the heteroaryl groups defined below, saturated and unsaturated cyclic organic groups having at least one O, S and/or N atom interrupting a carbocyclic ring structure that consists of one ring or two fused rings, wherein each ring is 5-, 6 or 7-membered and may or may not have double bonds that lack delocalized pi electrons, which ring structure has from 2 to 8, preferably from 3 to 6 carbon atoms; e.g., 2- or 3-piperidinyl, 2- or 3-piperazinyl, 2- or 3-morpholinyl, or 2- or 3-thiomorpholinyl;
• heteroaryl represents a cyclic organic group having at least one O, S and/or N atom interrupting a carbocyclic ring structure and having a sufficient number of delocalized ⁇ -electrons to provide aromatic character, with the aromatic heterocyclic group having from 2 to 14, preferably 4 or 5 carbon atoms, e.g., 2-, 3- or 4-pyridyl, 2- or 3-furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2- or 4-imidazolyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, or 3- or 4-pyridazinyl, etc.
• Preferred heteroaryl groups are 2-, 3- and 4-pyridyl;
• LAH lithium aluminum hydride
• each R 7 independently represents hydrogen, benzyl or a group as defined for R 2 above, wherein R 2 and R 7 may be the same or different.
• the group R 7 that is not attached to the nitrogen is hydrogen.
• the substituents on the phenyl ring are preferably chlorine.
• a second preferred group of compounds within Formula I has the general Formula IIA:
• Certain compounds of the invention may exist in different isomeric (e.g., enantiomers and diastereoisomers) forms.
• the invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms are also included.
• the compounds of Formula I can exist in unsolvated as well as solvated forms, including hydrated forms, e.g., hemi-hydrate.
• solvated forms including hydrated forms, e.g., hemi-hydrate.
• pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated forms for purposes of the invention.
• Certain basic compounds of the invention also form pharmaceutically acceptable salts, e.g., acid addition salts.
• the nitrogen atoms may form salts with acids.
• suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art.
• the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
• the free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate.
• the free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the invention. All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
• the compounds of this invention may be prepared according to suitable processes known in the art for making similar compounds, e.g. processes described in the literature referred to above. Unless stated otherwise, reactions are conducted at an appropriate temperature which allows the reaction to proceed at a reasonable rate to completion.
• the basic principle for producing the compounds of this invention comprises first preparing a compound of Formula III:
• PG is a protecting group.
• compounds of Formulas III and IV differ in whether G is connected to a ring carbon (Formula III) or ring nitrogen (Formula IV) of ring T.
• Compounds of Formula III and of Formula IV may then be reacted with a compound which introduces the desired group R 2 (and, if appropriate and desired, a group R 7 ) followed by removal of the protecting group using suitable methods.
• the compounds of Formulas III and IV may be either known or may be obtained by standard processes well known in the art, or prepared as described below.
• G 2 is a group G with one carbon atom less
• Pg is a suitable protecting group such as, for example, triphenylmethyl (“trityl”) or 2-(trimethylsilyl)ethoxymethyl.
• step 1 compound 1 is dissolved in an organic solvent such as, for example, tetrahydrofuran, and treated with a base such as, for example, n-butyllithium. Subsequently, an aldehyde 2 is added and compound 3 is obtained.
• step 2 compound 3 is dissolved in a suitable alcohol such as, for example, ethanol and hydrogenated under pressure (16-60 psi) in the presence of an appropriate catalyst such as, for example, platinum oxide to provide compound 4.
• step 3 compound 4 is suitably reacted with R 2 L (where L is a leaving group such as Cl, Br, I, OH or activated versions of OH like OSO 2 CF 3 generated independently or in situ) to place R 2 on the indicated nitrogen to produce compounds 5 and 6.
• R 2 L where L is a leaving group such as Cl, Br, I, OH or activated versions of OH like OSO 2 CF 3 generated independently or in situ
• the ratios of 5 and 6 can be varied by the amount of R 2 L employed.
• the reactions may be conducted in the appropriate solvents including, for example, ether, tetrahydrofuran, dioxane, dimethylsulfoxide, dimethylformamide, water, methylene chloride, toluene, with or without the presence of a suitable base such as, for example, triethylamine or lithium diisopropylamide or sodium hydride, at temperatures ranging from ⁇ 78° to 200° C.
• compound 4 can be treated with, for example, trimethylaluminum in solvents such as toluene of tetrahydrofuran, prior to the addition of R 2 L where R 2 L is RCO 2 R′′ and R′′ is a lower alkyl such as ethyl to provide compounds 5 and 6 where R 2 is —CO—(CH 2 ) p R 6 .
• solvents such as toluene of tetrahydrofuran
• step 4 compound 5 is reacted with R 7 L to place R 7 on the indicated nitrogen to produce compound 7.
• L is a leaving group as defined above and the reactions may be carried out under conditions as outlined above.
• Deprotection of compounds 5, 6 and 7 may be carried out using standard procedures well known in the art. For example, if Pg is trityl, treatment with dilute aqueous acid such as, for example HCl or HBr, at temperatures of about 25° to 100° C. provides the final compounds.
• step 1 compound 8 is dissolved in a suitable solvent such as, for example, diisopropylamine.
• Trimethylsilylacetylene, dichlorobis(triphenylphosphine) palladium chloride and copper iodide are added and allowed to react at temperatures between 25° and 60° C. to provide compound 9.
• step 2 compound 9 and compound 10 are dissolved in a suitable organic solvent such as, for example, dimethylformamide, and treated with a base such as potassium acetate, and a catalyst such as tetrakis-(triphenylphosphine)palladium at temperatures between 25 and 200° C. to afford compound 11.
• a suitable organic solvent such as, for example, dimethylformamide
• a base such as potassium acetate
• a catalyst such as tetrakis-(triphenylphosphine)palladium at temperatures between 25 and 200° C.
• step 3 compound 11 is dissolved in a suitable organic solvent such as ethanol and hydrogenated under pressure (16-60 psi) in the presence of an appropriate catalyst such as platinum oxide to provide compound 12.
• a suitable organic solvent such as ethanol
• an appropriate catalyst such as platinum oxide
• step 1 compound 13 is reacted with an aldehyde of structure 2, where Pg represents a protecting group such as triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl and the like, under standard reductive amination conditions such as, for example, treatment with sodium triacetoxyborohydride in acetic acid to provide compound 14.
• Pg represents a protecting group such as triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl and the like
• step 2 compound 14 is reacted with R 2 L to place R 2 on the indicated nitrogen to produce compound 15.
• L is a leaving group such as Cl, Br, I, OH or activated versions of hydroxyl such as, for example, OSO 2 CF 3 generated independently or in situ.
• the reaction may be conducted in an appropriate solvent or solvents including, for example, ether, tetrahydrofuran, dioxane, dimethylsulfoxide, dimethylformamide, water, methylene chloride, toluene with or without the presence of a suitable base such as triethylamine or lithium diisopropylamide or sodium hydride at temperatures ranging from ⁇ 78° to 200° C.
• step 3 compound 13 is reacted with R 2 L to place R 2 on the indicated nitrogens to produce compounds 16 and 17.
• the ratio of compounds 16 and 17 may be varied by the amount of R 2 L employed. L is as defined above.
• the reaction conditions outlined above may be applied.
• step 4 compound 16 is reacted with an aldehyde of structure 2, under standard reductive amination conditions such as treatment with sodium triacetoxyborohydride in acetic acid to provide compound 15. Deprotection of 15 provides a compound of this invention.
• pyrazinecarboxylic acid under standard amidation conditions such as 1-3(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole and N-methylmorpholine in organic solvents such as dimethylformamide and methylene chloride to provide compound 19.
• step 2 compound 19 is dissolved in an organic solvent such as methylene chloride and diluted with an alcohol like methanol. Hydrogenation of 19 at pressures ranging between 16 and 60 psi in the presence of a suitable catalyst such as platinum oxide affords compound 20.
• step 3 compound 20 is reacted with Y-L to place Y on the indicated nitrogen to produce compounds 21 and 22.
• the ratios of 21 and 22 can be varied by the amount of Y-L employed.
• Y can be VXR 1 where V can be chosen from CO, CO 2 , CH 2 , SO 2 , X can be (CH 2 ) 0-10 , and R 1 can be chosen from the group consisting of hydrogen, alkyl, cycloalkyl, benzyl, substituted benzyl, allyl, aryl, substituted aryl, heteroaryl or propargyl.
• L is a leaving group such as Cl, Br, I, OH and activated versions of OH like OSO 2 CF 3 generated independently or in situ.
• the reactions may be conducted in the appropriate solvents including ether, tetrahydrofuran, dioxane, dimethylsulfoxide, dimethylformamide, water, methylene chloride, toluene with or without the presence of a suitable bases such as triethylamine or lithium diisopropylamide or sodium hydride at temperatures ranging from ⁇ 78 to 200° C.
• a suitable bases such as triethylamine or lithium diisopropylamide or sodium hydride at temperatures ranging from ⁇ 78 to 200° C.
• compound 20 can be treated with trimethylaluminum in solvents such as toluene or tetrahydrofuran prior to the addition of Y-L where Y-L is RCO 2 R′′ and R′′ is lower alkyl such as ethyl to provide compounds 21 and 22 Y is COR.
• Compound 20 may also be reacted with aldehydes of structure R 1 CHO under standard reductive amination conditions such as treatment with sodium triacetoxyborohydride in acetic acid to provide compounds 21 and 22 where Y is CH 2 R 1 .
• the ratio of 21 and 22 can be varied by the amount of R 1 CHO employed.
• step 4 compound 21 is reacted with Y 1 -L to place Y 1 on the indicated nitrogens to produce compound 23.
• Y 1 can be VXR 1 where V can be chosen from CO, CO 2 , CH 2 , SO 2 , X can be chosen from (CH 2 ) 0-10 , CO, CO 2 , SO 2 , SO, S, O, N, NR 1 and R 1 can be chosen from the group consisting of hydrogen, alkyl, cycloalkyl, benzyl, substituted benzyl, allyl, aryl, substituted aryl, heteroaryl or propargyl.
• L is a leaving group such as Cl, Br, I, OH and activated versions of OH like OSO 2 CF 3 generated independently or in situ.
• the reactions may be conducted in the appropriate solvents including ether, tetrahydrofuran, dioxane, dimethylsulfoxide, dimethylformamide, water, methylene chloride, toluene with or without the presence of a suitable bases such as triethylamine or lithium diisopropylamide or sodium hydride at temperatures ranging from ⁇ 78 ° to 200° C.
• compound 23 can be treated with trimethylaluminum in solvents such as toluene or tetrahydrofuran prior to the addition of Y 1 -L where Y 1 -L is RCO 2 R′′ and R′′ is lower alkyl such as ethyl to provide compound 23 where Y 1 is COR.
• Compound 21 may also be reacted with aldehydes of structure R 1 CHO under standard reductive amination conditions such as treatment with sodium triacetoxyborohydride in acetic acid to provide compound 23 where Y 1 is CH 2 R 1 .
• step 5 when Z is triphenylmethyl, compound 23 is deprotected by treatment with dilute aqueous acid such as HC1 or HBr at a temperature of about 25° to 100° C. to produce compound 24.
• dilute aqueous acid such as HC1 or HBr
• compounds 19, 20, 21 and 22 can be deprotected.
• Other protecting groups are removed by methods well known in the art.
• the thus prepared compounds may be analyzed for their composition and purity as well as characterized by standard analytical techniques such as, for example, elemental analysis, NMR, mass spectroscopy, and IR spectra.
• inventive compounds can readily be evaluated to determine activity at H 3 receptors by known methods, including, for example, the guinea pig brain membrane assay and the guinea pig neuronal ileum contraction assay, both of which are described in U.S. Pat. No. 5,352,707.
• Another useful assay utilizes rat brain membranes and is described by West et al, (“Identification of Two H 3 -Histamine Receptor Subtypes”, Molecular Pharmacology , (1990), Vol. 33, 610-613.
• Several of the present compounds were found to have high H 3 antagonist activity.
• this invention provides pharmaceutical compositions comprising the inventive imidazolylalkyl compounds as an active ingredient.
• the pharmaceutical compositions generally additionally comprise a pharmaceutically acceptable carrier diluent, excipient or carrier (collectively referred to herein as carrier materials). Because of their H 3 antagonist activity, such pharmaceutical compositions possess utility in treating allergy, inflammation, nasal congestion, hypertension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastrointestinal tract, hypo- and hyperactivity of the central nervous system, Alzheimer's Disease, schizophrenia, migraines and the like diseases.
• the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive imidazolylalkyl compounds as an active ingredient.
• the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
• the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like.
• suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture.
• Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition.
• Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
• lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like.
• Disintegrants include starch, methylcellulose, guar gum and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate.
• compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e. antihistaminic activity and the like.
• Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
• Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
• Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
• a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
• a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
• solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
• liquid forms include solutions, suspensions and emulsions.
• the compounds of the invention may also be deliverable transdermally.
• the transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
• the compound is administered orally.
• the pharmaceutical preparation is in a unit dosage form.
• the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
• the quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application.
• the actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.
• the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the administration will be regulated according to the judgment of the attending clinician.
• a generally recommended daily dosage regimen for oral administration may range from about 0.04 milligrams to about 4,000 milligrams per day, in single or divided doses.
• Capsule refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients.
• Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
• Tablet refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents.
• the tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
• Oral gels refer to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.
• Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.
• Diluent refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn rice and potato; and celluloses such as microcrystalline cellulose.
• the amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.
• Disintegrants refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments.
• Suitable disintegrants include starches; “cold water soluble” modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose;
• microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures.
• the amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.
• Binders refer to substances that bind or “glue” powders together and make them cohesive by forming granules, thus serving as the “adhesive” in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate.
• the amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.
• Lubricant refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear.
• Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and dl-leucine.
• Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press.
• the amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.
• Glidents materials that prevent caking and improve the flow characteristics of granulations, so that flow is smooth and uniform.
• Suitable glidents include silicon dioxide and talc.
• the amount of glident in the composition can range from about 0.1% to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.
• Coloring agents that provide coloration to the composition or the dosage form.
• excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide.
• the amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.
• Bioavailability refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
• Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures. Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.
• Another embodiment of the invention discloses use of the pharmaceutical compositions disclosed above for treatment of diseases such as, for example, allergy, inflammation, nasal congestion, hypertension, glaucoma, sleeping disorders, states of hyper- and hypomotility of the gastrointestinal tract, hypo- and hyperactivity of the central nervous system, Alzheimer's Disease, schizophrenia, migraines and the like.
• the method comprises administering a therapeutically effective amount of the inventive pharmaceutical composition to a patient having such a diseases or diseases and in need of such a treatment.
• this invention discloses pharmaceutical compositions comprising the inventive imidazolylalkyl compounds in combination with one or more histamine-H 1 receptor antagonists.
• a suitable pharmaceutically acceptable carrier present.
• Numerous chemical substances are known to have histamine-H 1 receptor antagonist activity. Many such compounds can be classified broadly as ethanolamines, ethylenediamines, alkylamines, phenothiazines, piperidines, and the like.
• Hi receptor antagonists useful in the practice of the present invention include, without limitation, astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine (also known as desloratadine or “DCL”), doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, warmthlastine, trime
• Yet another embodiment of the invention discloses methods for preparing pharmaceutical compositions comprising the inventive imidazolylalkyl compounds and one or more histamine-H 1 receptor antagonists. And a still another embodiment discloses the aspect of using such compositions for treatment of allergy-induced airway (e.g. upper airway) responses.
• upper airway means the upper respiratory system—i.e., the nose, throat, and associated structures.
• the powder was loaded onto a silica gel chromatography column prepacked with 10% methanol/methylene chloride. Elution with 10% methanol/methylene chloride followed by 5% ammonium hydroxide (conc.)/10% methanol/methylene chloride provided 5.1 g (69%) of 28 as an amber oil and impure 29. Compound 29 was rechromatographed with 100% ethyl acetate followed by 5% triethylamine/ethyl acetate to provide 0.56 g (8%) of pure 29 as a clear oil.
• the mixture was transferred to a separatory funnel, diluted with ethyl acetate, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated onto enough silica gel such that a free-flowing powder was obtained.
• the resulting powder was loaded onto a chromatography column prepacked with silica and 10% methanol/methylene chloride. Elution with 10% methanol/methylene chloride followed by 5% ammonium hydroxide(conc.)/10% methanol/85% methylene chloride gave 0.89 g (65%) of 32 and 0.25 g (15%) of 33. Deprotection provided the corresponding deprotected compound.
• Triacetoxyborohydride (0.72 g, 3.4 mmol) was added to a room temperature solution of 28 (1.0 g, 2.4 mmol) and 4-Chlorobenzaldehyde (0.34 g, 2.4 mmol) in dichloroethane (6 mL). The resulting mixture was stirred overnight. The mixture was quenched with saturated sodium bicarbonate and rapidly stirred for 2 hours. The mixture was transferred to a separatory funnel, diluted with methylene chloride, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated onto enough silica gel such that a free-flowing powder was obtained.
• Table 2 contains a list of additionally prepared compounds belonging to Formula 1.
• the source of the H 3 receptors in this experiment was guinea pig brain.
• the animals used weighed 400-600 g.
• the tissue was homogenized using a Polytron in a solution of 50 mM Tris, pH 7.5.
• the final concentration of tissue in the homogenization buffer was 10% w/v.
• the homogenates were centrifuged at 1000 ⁇ g for 10 min. in order to remove clumps of tissue and debris.
• the resulting supernatants were then centrifuged at 50,000 ⁇ g for 20 min. in order to sediment the membranes, which were next washed 3 times in homogenization buffer (50,000 ⁇ g for 20 min. each).
• the membranes were frozen and stored at ⁇ 70° C. until needed.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Pulmonology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Ophthalmology & Optometry (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Cardiology (AREA)
• Rheumatology (AREA)
• Immunology (AREA)
• Anesthesiology (AREA)
• Otolaryngology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (1)

Publications (1)

Family

ID=23006868

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (32)

Citations (8)

Family Cites Families (1)

• 1999
  • 1999-03-08 US US09/264,615 patent/US6211182B1/en not_active Expired - Fee Related
• 2000
  • 2000-03-06 EP EP00917775A patent/EP1159275A2/en not_active Withdrawn
  • 2000-03-06 CA CA002362319A patent/CA2362319A1/en not_active Abandoned
  • 2000-03-06 WO PCT/US2000/005897 patent/WO2000053596A2/en not_active Application Discontinuation
  • 2000-03-06 AU AU38697/00A patent/AU3869700A/en not_active Abandoned
  • 2000-03-06 JP JP2000604034A patent/JP2002539121A/ja not_active Withdrawn
  • 2000-03-06 AR ARP000100992A patent/AR022848A1/es unknown

Patent Citations (8)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events